Skip to main content
Back
MEDP logo

Medpace Holdings, Inc.

Data quality: 100%
MEDP
NASDAQ Healthcare Medical - Diagnostics & Research
$466.80
▲ $6.06 (1.32%)
Mkt Cap: 13.25B
Day Range
$459.79 $470.58
52-Week Range
$250.05 $628.92
Volume
394,173
50D / 200D Avg
$512.21 / $488.76
Prev Close
$460.74

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (631 peers)

Metric Stock Sector Median
P/E 29.4 0.2
P/B 28.9 3.0
ROE % 70.2 3.6
Net Margin % 17.8 3.8
Rev Growth 5Y % 22.0 9.9
D/E 0.6 0.2

Analyst Price Target

Hold
$534.17 +14.4%
Low: $460.00 High: $582.00
Forward P/E
27.25
Forward EPS
$17.13
EPS Growth (est.)
+0.0%
Est. Revenue
2.81B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $25.05
$23.49 – $26.26
 3.86B 4
FY2029 $24.00
$22.50 – $25.16
 3.63B 4
FY2028 $21.70
$20.28 – $23.41
 3.30B 10

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-09 $4.19 $4.67 +11.5%
2025-10-22 $3.53 $3.86 +9.3%
2025-07-21 $2.98 $3.10 +4.0%
2025-04-21 $3.06 $3.67 +19.9%
2025-02-10 $2.96 $3.67 +24.0%
2024-10-21 $2.78 $3.01 +8.3%
2024-07-22 $2.54 $2.75 +8.3%
2024-04-22 $2.47 $3.20 +29.6%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Key Takeaways

Revenue grew 21.99% annually over 5 years — strong growth
ROE of 70.23% indicates high profitability
Net margin of 17.83% shows strong profitability
Generating 681.87M in free cash flow
Cash machine — converts 151.15% of earnings into free cash flow
Capital efficient — spends only 1.24% of revenue on capex

Growth

Revenue Growth (5Y)
21.99%
Revenue (1Y)19.97%
Earnings (1Y)11.56%
FCF Growth (3Y)31.10%

Quality

Return on Equity
70.23%
ROIC56.54%
Net Margin17.83%
Op. Margin21.14%

Safety

Debt / Equity
0.55
Current Ratio0.74
Interest Coverage0.00

Valuation

P/E Ratio
29.37
Forward P/E27.25
P/B Ratio28.86
EV/EBITDA24.31
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 19.97% Revenue Growth (3Y) 15.83%
Earnings Growth (1Y) 11.56% Earnings Growth (3Y) 26.30%
Revenue Growth (5Y) 21.99% Earnings Growth (5Y) 25.50%
Profitability
Revenue (TTM) 2.53B Net Income (TTM) 451.12M
ROE 70.23% ROA 22.84%
Gross Margin 30.06% Operating Margin 21.14%
Net Margin 17.83% Free Cash Flow (TTM) 681.87M
ROIC 56.54% FCF Growth (3Y) 31.10%
Safety
Debt / Equity 0.55 Current Ratio 0.74
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 29.37 Forward P/E 27.25
P/B Ratio 28.86 P/S Ratio 5.24
PEG Ratio 1.82 Forward PEG N/A
EV/EBITDA 24.31 Fwd EV/EBITDA 17.39
Forward P/S 4.72 Fwd Earnings Yield 3.67%
FCF Yield 5.15%
Market Cap 13.25B Enterprise Value 13.00B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.53B 2.11B 1.89B 1.46B 1.14B
Net Income 451.12M 404.39M 282.81M 245.37M 181.85M
EPS (Diluted) 15.28 12.63 8.88 7.28 4.81
Gross Profit 760.62M 656.31M 524.51M 432.44M 328.16M
Operating Income 534.94M 446.87M 336.83M 278.70M 198.62M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.98B 2.10B 1.66B 1.35B 1.66B
Total Liabilities 1.52B 1.28B 1.10B 966.11M 707.01M
Shareholders' Equity 459.07M 825.55M 558.95M 386.39M 952.93M
Total Debt 250.50M 149.52M 142.12M 188.87M 130.97M
Cash & Equivalents 497.05M 669.44M 245.45M 28.27M 461.30M
Current Assets 989.62M 1.03B 593.83M 333.96M 690.91M
Current Liabilities 1.34B 1.10B 925.13M 803.47M 557.22M

Strategy Scores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#587 of 1049
42
Custom Capital Light Compounder
#136 of 220
35
Custom Balanced Risk
#12 of 153
64

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Capital Light Compounder
Mar 24, 2026
Entered Balanced Risk
Mar 24, 2026